Two Decades of R&DWide moat

ASML's moat was built by research spending of a scale and patience almost no other company could sustain. The bet on EUV was placed more than two decades ago and did not pay off commercially until relatively recently — a span across which ASML kept investing through skepticism, technical setbacks, and years of losses on the program, funded by its profitable DUV business and a conviction that the physics could be cracked. That willingness to spend for twenty years on an unproven technology is itself a barrier: it requires not just money but a time horizon and a risk appetite that public markets rarely tolerate.

The spending has not slowed with success; ASML now invests on the order of €4–5 billion a year in R&D¹, staying relentlessly ahead. This continuous, heavy reinvestment is what turns a lead into a widening one: a competitor would have to match not just ASML's current technology but its ongoing spend, sustained over the same multi-decade horizon, all while ASML moves further forward. The research budget is the engine that keeps refilling the moat, and it is affordable only because the monopoly generates the profits to fund it — a virtuous circle in which monopoly economics pay for the research that sustains the monopoly.